

Alan E Mast

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8971594/publications.pdf>

Version: 2024-02-01

87
papers

4,036
citations

126907

33
h-index

123424

61
g-index

90
all docs

90
docs citations

90
times ranked

3655
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor V east Texas variant causes bleeding in a three-generation family. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 565-573.	3.8	7
2	Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. <i>JCI Insight</i> , 2022, 7, .	5.0	29
3	Response to comment on "SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung". <i>ELife</i> , 2022, 11, .	6.0	1
4	Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1290-1300.	3.8	19
5	Sex-specific genetic modifiers identified susceptibility of cold stored red blood cells to osmotic hemolysis. <i>BMC Genomics</i> , 2022, 23, 227.	2.8	2
6	Demographic, clinical, and biochemical predictors of pica in high-intensity blood donors. <i>Transfusion Medicine</i> , 2022, 32, 288-292.	1.1	2
7	Tissue factor pathway inhibitor is required for cerebrovascular development in mice. <i>Blood</i> , 2021, 137, 258-268.	1.4	10
8	Iron status and self-reported fatigue in blood donors. <i>Transfusion</i> , 2021, 61, 124-133.	1.6	5
9	Red blood cell transfusion does not increase risk of venous or arterial thrombosis during hospitalization. <i>American Journal of Hematology</i> , 2021, 96, 218-225.	4.1	7
10	Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome. <i>Sleep</i> , 2021, 44, .	1.1	5
11	SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. <i>ELife</i> , 2021, 10, .	6.0	46
12	Demographic, clinical, and biochemical predictors of pica in a large cohort of blood donors. <i>Transfusion</i> , 2021, 61, 2090-2098.	1.6	9
13	Intrauterine lethality in <i>Tfpi</i> gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet <i>TFPI±</i> overexpression. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1483-1492.	3.8	3
14	CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1932-1947.	3.8	7
15	Major Reservoir for Heparin-Releasable <i>TFPI±</i> (Tissue Factor Pathway Inhibitor ±) Is Extracellular Matrix. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1942-1955.	2.4	10
16	The contribution of <i>TFPI±</i> to the hemostatic response to injury in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2182-2192.	3.8	3
17	Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	42
18	Intersection of regulatory pathways controlling hemostasis and hemochorial placentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	19

#	ARTICLE	IF	CITATIONS
19	Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2083-2086.	3.8	3
20	Reducing Iron Deficiency in Teen-Aged Blood Donors. <i>Pediatrics</i> , 2020, 146, .	2.1	0
21	Genetic and behavioral modification of hemoglobin and iron status among first-time and high-intensity blood donors. <i>Transfusion</i> , 2020, 60, 747-758.	1.6	9
22	The benefits of iron supplementation following blood donation vary with baseline iron status. <i>American Journal of Hematology</i> , 2020, 95, 784-791.	4.1	18
23	FcRn augments induction of tissue factor activity by IgG-containing immune complexes. <i>Blood</i> , 2020, 135, 2085-2093.	1.4	19
24	A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. <i>ELife</i> , 2020, 9, .	6.0	296
25	Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. <i>Transfusion</i> , 2019, 59, 3146-3156.	1.6	20
26	Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia. <i>Haemophilia</i> , 2019, 25, 1083-1091.	2.1	8
27	Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency. <i>Blood Advances</i> , 2019, 3, 489-498.	5.2	9
28	Intradonor reproducibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDS-III RBC-Omics study. <i>Transfusion</i> , 2019, 59, 79-88.	1.6	47
29	Frequent blood donations alter susceptibility of red blood cells to storage- and stress-induced hemolysis. <i>Transfusion</i> , 2019, 59, 67-78.	1.6	44
30	Development and evaluation of a transfusion medicine genome wide genotyping array. <i>Transfusion</i> , 2019, 59, 101-111.	1.6	30
31	Elevated risk for iron depletion in high-school age blood donors. <i>Transfusion</i> , 2019, 59, 1706-1716.	1.6	39
32	Blood, sweat, and tears: Red Blood Cell-Omics study objectives, design, and recruitment activities. <i>Transfusion</i> , 2019, 59, 46-56.	1.6	44
33	Sex hormone intake in female blood donors: impact on haemolysis during cold storage and regulation of erythrocyte calcium influx by progesterone. <i>Blood Transfusion</i> , 2019, 17, 263-273.	0.4	9
34	Suppressive Role of Tissue Factor Pathway Inhibitor-1 \pm in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength. <i>Thrombosis and Haemostasis</i> , 2018, 118, 502-513.	3.4	14
35	Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 93-104.	2.3	33
36	Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1545-1555.	3.4	7

#	ARTICLE	IF	CITATIONS
37	Qualitative assessment of pica experienced by frequent blood donors. <i>Transfusion</i> , 2017, 57, 946-951.	1.6	12
38	Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy. <i>American Journal of Hematology</i> , 2017, 92, 851-857.	4.1	18
39	2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine. <i>Transfusion</i> , 2017, 57, 1568-1581.	1.6	20
40	Teenage Blood Donors: Are We Asking Too Little and Taking Too Much?. <i>Pediatrics</i> , 2017, 139, .	2.1	17
41	Putting donor health first in strategies to mitigate donor iron deficiency. <i>Transfusion</i> , 2017, 57, 495-498.	1.6	8
42	The price of blood is measured in iron. <i>Lancet, The</i> , 2017, 390, 2331-2333.	13.7	11
43	The operational implications of donor behaviors following enrollment in STRIDE (Strategies to Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	14
44	Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state. <i>Blood Advances</i> , 2017, 1, 386-395.	5.2	17
45	Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. <i>Blood Advances</i> , 2017, 1, 1132-1141.	5.2	164
46	TFPI± interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation. <i>Blood Advances</i> , 2017, 1, 2692-2702.	5.2	31
47	Effect of iron supplementation on iron stores and total body iron after whole blood donation. <i>Transfusion</i> , 2016, 56, 2005-2012.	1.6	48
48	Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. <i>British Journal of Haematology</i> , 2016, 175, 123-132.	2.5	4
49	A randomized, blinded, placebo-controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors. <i>Transfusion</i> , 2016, 56, 1588-1597.	1.6	48
50	Targeting TFPI for hemophilia treatment. <i>Thrombosis Research</i> , 2016, 141, S28-S30.	1.7	38
51	Tissue Factor Pathway Inhibitor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 9-14.	2.4	136
52	The health implications of low hemoglobin deferral in infrequent blood donors. <i>Transfusion</i> , 2015, 55, 86-90.	1.6	8
53	Oral Iron Supplementation After Blood Donation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 575.	7.4	133
54	A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development. <i>Blood</i> , 2015, 125, 4078-4084.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Protein S Is a Cofactor for Platelet and Endothelial Tissue Factor Pathway Inhibitor-1 but Not for Cell Surface-associated Tissue Factor Pathway Inhibitor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 169-176.	2.4	41
56	Translation of Human Tissue Factor Pathway Inhibitor-2 mRNA Is Controlled by Alternative Splicing Within the 5' Untranslated Region. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 187-195.	2.4	10
57	Low hemoglobin deferral in blood donors. <i>Transfusion Medicine Reviews</i> , 2014, 28, 18-22.	2.0	32
58	Biology of tissue factor pathway inhibitor. <i>Blood</i> , 2014, 123, 2934-2943.	1.4	235
59	Relieving Inhibition of Prothrombinase By TFPI: a Procoagulant Activity of Unfractionated, Low Molecular Weight, and Nonanticoagulant Heparins. <i>Blood</i> , 2014, 124, 1478-1478.	1.4	0
60	Laboratory variables for assessing iron deficiency in <sc>REDS</sc>ron <sc>S</sc>tatus <sc>E</sc>valuation (<sc>RISE</sc>) blood donors. <i>Transfusion</i> , 2013, 53, 2766-2775.	1.6	36
61	Restless legs syndrome, pica, and iron status in blood donors. <i>Transfusion</i> , 2013, 53, 1645-1652.	1.6	59
62	Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17838-17843.	7.1	137
63	Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. <i>Haematologica</i> , 2013, 98, 1324-1330.	3.5	21
64	Caveolae optimize tissue factor-factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor. <i>Biochemical Journal</i> , 2012, 443, 259-266.	3.7	12
65	Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3927-3931.	7.1	74
66	Population-based screening for anemia using first-time blood donors. <i>American Journal of Hematology</i> , 2012, 87, 496-502.	4.1	14
67	The impact of <i>HFE</i> mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*. <i>British Journal of Haematology</i> , 2012, 156, 388-401.	2.5	22
68	The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores. <i>Transfusion</i> , 2012, 52, 1031-1040.	1.6	57
69	Iron deficiency in blood donors: the REDS Donor Iron Status Evaluation (RISE) study. <i>Transfusion</i> , 2012, 52, 702-711.	1.6	184
70	Iron deficiency in blood donors: analysis of enrollment data from the REDS Donor Iron Status Evaluation (RISE) study. <i>Transfusion</i> , 2011, 51, 511-522.	1.6	161
71	Blood center practice and education for blood donors with anemia. <i>Transfusion</i> , 2011, 51, 929-936.	1.6	23
72	Murine Hematopoietic Cell Tissue Factor Pathway Inhibitor Limits Thrombus Growth. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 821-826.	2.4	44

#	ARTICLE	IF	CITATIONS
73	Alternatively spliced tissue factor pathway inhibitor: Functional Implications. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 1457.	2.1	4
74	Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. <i>Blood</i> , 2010, 116, 1787-1794.	1.4	45
75	Community blood donors' knowledge of anemia and design of a literacy-appropriate educational intervention. <i>Transfusion</i> , 2010, 50, 75-79.	1.6	9
76	Demographic correlates of low hemoglobin deferral among prospective whole blood donors. <i>Transfusion</i> , 2010, 50, 1794-1802.	1.6	63
77	Alternatively spliced isoforms of tissue factor pathway inhibitor. <i>Thrombosis Research</i> , 2010, 125, S52-S56.	1.7	41
78	Reticulocyte hemoglobin content. <i>American Journal of Hematology</i> , 2008, 83, 307-310.	4.1	114
79	Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. <i>Transfusion</i> , 2008, 48, 2197-2204.	1.6	62
80	Expression of tissue factor pathway inhibitor by endothelial cells and platelets. <i>Transfusion and Apheresis Science</i> , 2008, 38, 9-14.	1.0	51
81	Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. <i>Blood</i> , 2007, 109, 1931-1937.	1.4	113
82	Characterization of the Association of Tissue Factor Pathway Inhibitor With Human Placenta. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 2099-2104.	2.4	48
83	Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. <i>Blood</i> , 2002, 99, 1489-1491.	1.4	200
84	Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. <i>Biochemical Journal</i> , 2002, 367, 451-458.	3.7	38
85	Contribution of Regions Distal to Glycine-160 to the Anticoagulant Activity of Tissue Factor Pathway Inhibitor. <i>Biochemistry</i> , 2002, 41, 4989-4997.	2.5	35
86	Tissue Factor Pathway Inhibitor Binds to Platelet Thrombospondin-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 31715-31721.	3.4	32
87	Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. <i>Clinical Chemistry</i> , 1998, 44, 45-51.	3.2	391